2020 Fiscal Year Final Research Report
Development of DFAT cells therapy for the immunologic nephritis
| Project/Area Number |
18K08255
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53040:Nephrology-related
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
逸見 聖一朗 日本大学, 医学部, 助教 (10817240)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Keywords | 慢性腎臓病 / 免疫性腎炎 / 間葉系幹細胞 / 細胞治療 / DFAT |
|---|
| Outline of Final Research Achievements |
Systematic implantation of dedifferentiated fat cells ameliorated ANCA nephritis in animal models. Anti-inflammatory action by TSG-6 and immunoregulation effects which was associated with Transformation from M1 macrophage to M2 macrophage were regarded as the mechanism to ameliorate nephritis. The tumorigenesis and the excessive rejection after the transplant were not found and the safety of this technique was confirmed, too. This animal models are diseases of the human, are causes of CKD, have a poor prognosis. Likelihood of the DFAT cell therapy was suggested for immunologic nephritis.
|
| Free Research Field |
慢性腎不全
|
| Academic Significance and Societal Importance of the Research Achievements |
急性腎障害はその原因を取り除くことで腎臓は治癒する場合も少なくないが、慢性腎障害である場合は治療法が根治的なものは少なく、経時的に腎機能が悪化し透析導入をせざるを得ない場合もあり得る。そのため透析患者数が増え続けているのが現状であり、このような「慢性腎臓病」の根治的治療開発が望まれている。今回動物モデルで使用した疾患はこの「慢性腎臓病」の一因でもありかつ最も生命予後不良の疾患である。今回この病態改善の結果が得られたことで、予後不良の疾患に対して治療法が開発される可能性だけでなく透析導入を減らす礎になれば学問的価値だけでなく患者のQOL改善や医療費削減といった社会的意義も大きいと思われる。
|
